Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial

Alan Martin, Dhvani Shah, Kerigo Ndirangu, Glenn A. Anley, Gabriel Okorogheye, Melanie Schroeder, Nancy Risebrough, Afisi S. Ismaila

Source: ERJ Open Res, 8 (1) 00333-2021; 10.1183/23120541.00333-2021
Journal Issue: January

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Alan Martin, Dhvani Shah, Kerigo Ndirangu, Glenn A. Anley, Gabriel Okorogheye, Melanie Schroeder, Nancy Risebrough, Afisi S. Ismaila. Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial. ERJ Open Res, 8 (1) 00333-2021; 10.1183/23120541.00333-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
Source: ERJ Open Res, 7 (1) 00480-2020; 10.1183/23120541.00480-2020
Year: 2021



Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020


Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial
Source: Breathe, 17 (1) 1198; 10.1183/20734735.0279-2020
Year: 2021



The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD
Source: Breathe, 14 (4) 333; 10.1183/20734735.026418
Year: 2018



Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009

Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Year: 2021



Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

IMPACT: Healthcare resource use data and associated costs for single-inhaler triple therapy versus dual therapies in Spain
Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence
Year: 2021



Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial
Source: International Congress 2018 – COPD management
Year: 2018


Real-world effectiveness and cost-effectiveness of asthma step-up options: A UK comparison of extrafine hydrofluoroalkane-beclometasone and combination therapy
Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Year: 2013


Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018



Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population?
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021



Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015


Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021
Year: 2021



The Children's Anti-inflammatory Reliever (CARE) study: a protocol for a randomised controlled trial of budesonide-formoterol as sole reliever therapy in children with mild asthma
Source: ERJ Open Res, 7 (4) 00271-2021; 10.1183/23120541.00271-2021
Year: 2021



Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies.
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020


INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015

Chinese subgroup results from a study comparing single-inhaler triple therapy with dual therapy in COPD
Source: International Congress 2017 – COPD management
Year: 2017


Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018


Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice: a randomised real-life study
Source: Eur Respir J 2006; 28: Suppl. 50, 613s
Year: 2006